Bayer Aktienges ADR (BAYRY)

$7.79 +0.08 (1.04%)
Market Cap 31.08B
Revenue (ttm) 50.43B
Net Income (ttm) -2.76B
EPS (ttm) N/A
PE Ratio 6.30
Forward PE 6.31
Profit Margin -5.48%
Debt to Equity Ratio 1.21
Volume 298,563
Avg Vol 698,550
Day's Range N/A - N/A
Shares Out 3.93B
Stochastic %K 45%
Beta 0.85
Analysts Sell
Price Target $8.40

Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-c...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 49 214 30 1
Address:
Kaiser-Wilhelm-Allee 1, Leverkusen, Germany
Ludlowj
Ludlowj Jun. 18 at 5:39 PM
$BAYRY will the supreme court look. At this case soon?
0 · Reply
ZacksResearch
ZacksResearch Jun. 18 at 3:04 PM
$BAYRY just filed for FDA approval — here’s why it matters 📈 The new MRI contrast agent, gadoquatrane, is low-dose and supported by strong QUANTI study results. See what’s behind this potential catalyst 👉 https://www.zacks.com/stock/news/2510964/bayer-seeks-fda-approval-for-mri-contrast-agent-gadoquatrane?cid=sm-stocktwits-2-2510964-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2510964_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 18 at 1:54 PM
$BAYRY surges 58% YTD — can gadoquatrane approval boost it further? 🚀 The NDA for Bayer's low-dose GBCA, gadoquatrane, could strengthen its radiology leadership if approved. QUANTI studies show it effectively enhances imaging with a 60% lower dose than current standards. Discover more on Bayer's growth potential here 👉 https://www.zacks.com/commentary/2510964/bayer-seeks-fda-approval-for-mri-contrast-agent-gadoquatrane?cid=sm-stocktwits-2-2510964-body&ADID=SYND_STOCKTWITS_TWEET_2_2510964_BODY
0 · Reply
Dirk1969
Dirk1969 Jun. 17 at 3:08 PM
$BAYRY https://www.marketscreener.com/quote/stock/BAYER-AG-436063/news/Bayer-Files-For-Approval-Of-Gadoquatrane-In-The-U-S-50258627/
0 · Reply
HereForFunsies
HereForFunsies Jun. 12 at 6:07 PM
$BAYRY been a long time since we've seen the 8s. Here's to hoping it holds and goes for 10s. Congratulations to those who have been buying down through the last several years of chaos. It's been a wild ride with a lot of ground to make up still, but it's been a nice 2025 🥂
1 · Reply
Dirk1969
Dirk1969 Jun. 11 at 3:07 PM
$BAYRY https://www.investing.com/news/stock-market-news/kepler-cheuvreux-upgrades-bayer-to-buy-keeps-target-price-at-33-4090770
0 · Reply
Dirk1969
Dirk1969 Jun. 11 at 3:05 PM
$BAYRY https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3SE0T2:0-hsbc-raises-bayer-to-buy-says-litigation-resolution-in-sight/
0 · Reply
Dirk1969
Dirk1969 Jun. 11 at 3:01 PM
$BAYRY https://www.investing.com/news/stock-market-news/kepler-cheuvreux-upgrades-bayer-to-buy-keeps-target-price-at-33-4090770
0 · Reply
HereForFunsies
HereForFunsies Jun. 11 at 1:23 PM
$BAYRY Gotta love the upgrades that keep coming in. Here's to hoping future litigation doesn't wipe this out 😂
1 · Reply
Zafather
Zafather Jun. 9 at 5:02 PM
$MYNA Cautionary tale here - ADRs are portfolio poison most of time $BVNRY $BAYRY maybe exception but still - ugly vs exchange rates until you have a hedge.
0 · Reply
Latest News on BAYRY
No data available.
Ludlowj
Ludlowj Jun. 18 at 5:39 PM
$BAYRY will the supreme court look. At this case soon?
0 · Reply
ZacksResearch
ZacksResearch Jun. 18 at 3:04 PM
$BAYRY just filed for FDA approval — here’s why it matters 📈 The new MRI contrast agent, gadoquatrane, is low-dose and supported by strong QUANTI study results. See what’s behind this potential catalyst 👉 https://www.zacks.com/stock/news/2510964/bayer-seeks-fda-approval-for-mri-contrast-agent-gadoquatrane?cid=sm-stocktwits-2-2510964-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2510964_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 18 at 1:54 PM
$BAYRY surges 58% YTD — can gadoquatrane approval boost it further? 🚀 The NDA for Bayer's low-dose GBCA, gadoquatrane, could strengthen its radiology leadership if approved. QUANTI studies show it effectively enhances imaging with a 60% lower dose than current standards. Discover more on Bayer's growth potential here 👉 https://www.zacks.com/commentary/2510964/bayer-seeks-fda-approval-for-mri-contrast-agent-gadoquatrane?cid=sm-stocktwits-2-2510964-body&ADID=SYND_STOCKTWITS_TWEET_2_2510964_BODY
0 · Reply
Dirk1969
Dirk1969 Jun. 17 at 3:08 PM
$BAYRY https://www.marketscreener.com/quote/stock/BAYER-AG-436063/news/Bayer-Files-For-Approval-Of-Gadoquatrane-In-The-U-S-50258627/
0 · Reply
HereForFunsies
HereForFunsies Jun. 12 at 6:07 PM
$BAYRY been a long time since we've seen the 8s. Here's to hoping it holds and goes for 10s. Congratulations to those who have been buying down through the last several years of chaos. It's been a wild ride with a lot of ground to make up still, but it's been a nice 2025 🥂
1 · Reply
Dirk1969
Dirk1969 Jun. 11 at 3:07 PM
$BAYRY https://www.investing.com/news/stock-market-news/kepler-cheuvreux-upgrades-bayer-to-buy-keeps-target-price-at-33-4090770
0 · Reply
Dirk1969
Dirk1969 Jun. 11 at 3:05 PM
$BAYRY https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3SE0T2:0-hsbc-raises-bayer-to-buy-says-litigation-resolution-in-sight/
0 · Reply
Dirk1969
Dirk1969 Jun. 11 at 3:01 PM
$BAYRY https://www.investing.com/news/stock-market-news/kepler-cheuvreux-upgrades-bayer-to-buy-keeps-target-price-at-33-4090770
0 · Reply
HereForFunsies
HereForFunsies Jun. 11 at 1:23 PM
$BAYRY Gotta love the upgrades that keep coming in. Here's to hoping future litigation doesn't wipe this out 😂
1 · Reply
Zafather
Zafather Jun. 9 at 5:02 PM
$MYNA Cautionary tale here - ADRs are portfolio poison most of time $BVNRY $BAYRY maybe exception but still - ugly vs exchange rates until you have a hedge.
0 · Reply
jagadakku
jagadakku Jun. 5 at 1:39 PM
$BAYRY $BSX reiterating this ...5 years and this is a 4 x 5 bagger... I got in sub 5 but hate not buying more. Good luck
1 · Reply
Dirk1969
Dirk1969 Jun. 5 at 9:12 AM
$BAYRY https://www.gurufocus.com/news/2909534/bayer-bayry-receives-upgrade-from-goldman-sachs-bayry-stock-news
2 · Reply
Dirk1969
Dirk1969 Jun. 3 at 6:04 AM
$BAYRY https://www.marketscreener.com/quote/stock/BAYER-AG-436063/news/Bayer-about-to-market-gadoquatrane-in-Japan-50127919/
0 · Reply
Dirk1969
Dirk1969 Jun. 1 at 9:34 PM
$BAYRY https://valuesider.com/guru/thomas-graham-alan-irving-kahns-kahn-brothers-group/portfolio-activity
0 · Reply
HereForFunsies
HereForFunsies May. 29 at 7:50 PM
$BAYRY welp, back to the grind I guess. Glad the market didnt react poorly to the news today. https://www.reuters.com/legal/government/bayers-monsanto-loses-appeal-611m-roundup-verdict-missouri-2025-05-28/
0 · Reply
ALucci
ALucci May. 29 at 7:40 PM
$BAYRY
0 · Reply
anesthesia_sleep
anesthesia_sleep May. 29 at 7:00 PM
All eyes on $INAB with its glioblastoma treatment! $BAYRY $BMY $INAB $MRK
0 · Reply
anesthesia_sleep
anesthesia_sleep May. 28 at 9:02 PM
$INAB “The global glioblastoma multiforme (GBM) treatment market is projected to grow significantly, reaching an estimated $5.7 billion by 2033. This growth is driven by factors like the rising incidence of GBM, an aging population, and the development of new, more targeted therapies.” Major companies involved in GBM treatment include $BAYRY Bayer, $MRK, $CMRX Chimerix, Aivita Biomedical, Denovo Biopharma, $BMY Bristol Myers Squibb
1 · Reply
scottptts
scottptts May. 24 at 1:21 AM
$BAYRY https://youtu.be/HoFHX7_tvtM?si=MJWoBlJpTwdEO7G8
1 · Reply
Dirk1969
Dirk1969 May. 23 at 12:15 PM
$BAYRY https://www.gurufocus.com/news/2885781/bayer-bayry-moves-up-to-otcqx-best-market-bayry-stock-news
0 · Reply
HereForFunsies
HereForFunsies May. 23 at 12:02 PM
$BAYRY scratch that lol our president can't stick to what he says he'll do 🙃
0 · Reply
HereForFunsies
HereForFunsies May. 23 at 10:41 AM
$BAYRY Germany is green today. Maybe we see this go back over 7 today 🤞
0 · Reply